IRMD 最新10-Q变化
将 IRMD 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-07-31 与上一份 10-Q · 2026-05-01
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +23 | −16 | ~8 | 17 |
| 市场风险(第3项) | 文字有新增/删除 | +5 | −6 | ~2 | 29 |
| 控制与程序 | 文字有新增/删除 | +5 | −6 | ~2 | 29 |
| 法律诉讼 | 文字有新增/删除 | +5 | −6 | ~2 | 29 |
| 风险因素 | 文字有新增/删除 | +5 | −6 | ~2 | 29 |
| 其他信息 | 文字有新增/删除 | +5 | −6 | ~2 | 29 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-07-31
For the quarter ended June 30, 2026, our revenue increased by $0.1 million, or 0.5%, to $20.5 million from $20.4 million compared to the same period of 2025. Income before the provision for income taxes was $6.9 million for the quarter ended June 30, 2026, compared to $7.3 million for the quarter en…
MRI Compatible Patient Vital Signs Monitoring Systems6,665 5,944 13,772 12,489
Amortization of extended maintenance agreements758 592 1,417 1,153
For the three months ended June 30, 2026, total revenue increased by $0.1 million, or 0.5%, to $20.5 million from $20.4 million for the same period in 2025. This increase is primarily attributed to modifications to our sales incentive plan for patient vital signs monitoring systems, disposables, and…
Revenue from sales in the U.S. decreased by $1.5 million, or 8%, to $16.7 million for the three months ended June 30, 2026, from $18.2 million for the same period in 2025. Revenue from sales internationally increased by $1.5 million, or 69%, to $3.7 million from $2.2 million for the same period in 2…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
For the quarter ended March 31, 2026, our revenue increased by $2.5 million, or 13% to $22.0 million, compared to $19.5 million for the quarter ended March 31, 2025. Income before the provision for income taxes was $7.8 million for the quarter ended March 31, 2026, compared to $5.9 million for the q…
Comparison of the Three Months Ended March 31, 2026 and 2025
MRI Compatible Intravenous ("IV") Infusion Pump Systems$7,664 $5,999
MRI Compatible Patient Vital Signs Monitoring Systems7,107 6,545
For the three months ended March 31, 2026, total revenue increased by $2.5 million, or 13%, to $22.0 million from $19.5 million for the same period in 2025. This increase is primarily attributed to continued demand for our IV infusion pump systems, amortization of extended maintenance revenue, and m…
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-07-31
•our primary reliance on a limited number of products and our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services;
•the impact on our operations and financial results of any public health emergency, including any potential future pandemic or epidemic, or any natural disaster, and any related policies and actions by governments or other third parties;
•geopolitical risks, including international conflicts, political instability and recent or upcoming elections in the United States (the “U.S.”) and other countries, which could, among other things, lead to increased market volatility;
•the impact of tariffs, trade restrictions, export controls, and changes in trade policy, which could increase the cost of components and raw materials used in our products, disrupt our supply chain, limit our ability to sell products in international markets, or otherwise adversely affect our busin…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
•failure to obtain and/or maintain regulatory approvals and comply with applicable regulations;
•our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory approvals or clearances associated with those activities;
•potential negative impacts resulting from a future pandemic or epidemic, or natural disaster;
•the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties;
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-07-31
•our primary reliance on a limited number of products and our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services;
•the impact on our operations and financial results of any public health emergency, including any potential future pandemic or epidemic, or any natural disaster, and any related policies and actions by governments or other third parties;
•geopolitical risks, including international conflicts, political instability and recent or upcoming elections in the United States (the “U.S.”) and other countries, which could, among other things, lead to increased market volatility;
•the impact of tariffs, trade restrictions, export controls, and changes in trade policy, which could increase the cost of components and raw materials used in our products, disrupt our supply chain, limit our ability to sell products in international markets, or otherwise adversely affect our busin…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
•failure to obtain and/or maintain regulatory approvals and comply with applicable regulations;
•our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory approvals or clearances associated with those activities;
•potential negative impacts resulting from a future pandemic or epidemic, or natural disaster;
•the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties;
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-07-31
•our primary reliance on a limited number of products and our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services;
•the impact on our operations and financial results of any public health emergency, including any potential future pandemic or epidemic, or any natural disaster, and any related policies and actions by governments or other third parties;
•geopolitical risks, including international conflicts, political instability and recent or upcoming elections in the United States (the “U.S.”) and other countries, which could, among other things, lead to increased market volatility;
•the impact of tariffs, trade restrictions, export controls, and changes in trade policy, which could increase the cost of components and raw materials used in our products, disrupt our supply chain, limit our ability to sell products in international markets, or otherwise adversely affect our busin…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
•failure to obtain and/or maintain regulatory approvals and comply with applicable regulations;
•our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory approvals or clearances associated with those activities;
•potential negative impacts resulting from a future pandemic or epidemic, or natural disaster;
•the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties;
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-07-31
•our primary reliance on a limited number of products and our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services;
•the impact on our operations and financial results of any public health emergency, including any potential future pandemic or epidemic, or any natural disaster, and any related policies and actions by governments or other third parties;
•geopolitical risks, including international conflicts, political instability and recent or upcoming elections in the United States (the “U.S.”) and other countries, which could, among other things, lead to increased market volatility;
•the impact of tariffs, trade restrictions, export controls, and changes in trade policy, which could increase the cost of components and raw materials used in our products, disrupt our supply chain, limit our ability to sell products in international markets, or otherwise adversely affect our busin…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
•failure to obtain and/or maintain regulatory approvals and comply with applicable regulations;
•our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory approvals or clearances associated with those activities;
•potential negative impacts resulting from a future pandemic or epidemic, or natural disaster;
•the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties;
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-07-31
•our primary reliance on a limited number of products and our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services;
•the impact on our operations and financial results of any public health emergency, including any potential future pandemic or epidemic, or any natural disaster, and any related policies and actions by governments or other third parties;
•geopolitical risks, including international conflicts, political instability and recent or upcoming elections in the United States (the “U.S.”) and other countries, which could, among other things, lead to increased market volatility;
•the impact of tariffs, trade restrictions, export controls, and changes in trade policy, which could increase the cost of components and raw materials used in our products, disrupt our supply chain, limit our ability to sell products in international markets, or otherwise adversely affect our busin…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
•failure to obtain and/or maintain regulatory approvals and comply with applicable regulations;
•our ability to identify and pursue development of additional products;
•difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory approvals or clearances associated with those activities;
•potential negative impacts resulting from a future pandemic or epidemic, or natural disaster;
•the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties;
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议